Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Roivant Sciences $230 million stock offering
We advised the company on its SEC-registered offering
Invacare chapter 11 filing
We are advising Highbridge Capital in connection with the restructuring
Integer Holdings $500 million convertible senior notes offering
The 2.125% convertible notes are due 2028
Pacific Biosciences $201.25 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Precigen $75 million follow-on offering
We advised Precigen on the SEC-registered offering
Deciphera Pharmaceuticals $135.1 million common stock offering
The common stock is listed on the Nasdaq Global Select Market
Tricida chapter 11 liquidation
We are advising noteholders in connection with Tricida’s chapter 11 proceedings
Sun Pharmaceutical acquisition of Concert Pharmaceuticals
We advised Sun Pharmaceutical on the transaction
New Horizon Health HK$781.7 million top-up placement of shares
We advised New Horizon Health on the top-up placement
Jinxin Fertility Group HK$1.17 billion top-up placement of shares
The shares are listed on the Hong Kong Stock Exchange